In patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic, administration of angiotensin converting enzyme inhibitors, angiotensin receptor blockers or combined therapy with both agents, comparison of three arms to assess the impact on cardiovascular and cerebrovascular outcomes.

Consorzio Mario Negri Sud0 sites2,100 target enrollmentJune 21, 2007

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.
Sponsor: Consorzio Mario Negri Sud
Enrollment: 2100
Status: Recruiting
Last Updated: 6 years ago

No summary available.

Registry

who.int

Start Date

June 21, 2007

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

Consorzio Mario Negri Sud

•Consenting individuals, with microalbuminuria or macroalbuminuria, with one or more cardiovascular risk factors (smoking, diabetes, hypertension, visceral obesity, dyslipidemia, family history of cardiovascular diseases) including those with previous major cardiovascular events provided these have occurred at least 6 months before enrolment.

•Pregnancy, no use of birth control measures, neoplasm, clinically significant aortic obstruction, previous evidence of intolerance to study medications, clear contraindications to use of RAS inhibition, major cardiovascular events within 6 months of randomization, any condition which significantly reduces life expectancy and any condition where the patient appears not to be able to guarantee compliance with treatment and follow\-up.